文献速递神经肿瘤

MGMT启动子甲基化能否弥补IDH野生型胶质母细胞瘤次全切除的局限?

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
PubMed 文献 · J Neurooncol · 2021-06-29

该回顾性研究纳入2010至2018年间81例术后有残留肿瘤的IDH野生型胶质母细胞瘤(WHO IV级)患者,分析分子标志与生存的关系并与完全切除患者比较。结果显示MGMT启动子甲基化患者的总生存和无进展生存显著延长,但相比完全切除患者,甲基化并不能弥补残留肿瘤带来的生存劣势。

要点

  • MGMT启动子甲基化与IDH野生型胶质母细胞瘤患者更长的OS和PFS相关。
  • 相比完全切除,残留肿瘤患者无论MGMT状态如何OS均降低。
  • MGMT甲基化不能补偿次全切除导致的生存劣势。

核心结论

  • MGMT启动子甲基化可改善IDH野生型胶质母细胞瘤患者的OS和PFS,但不能弥补残留肿瘤体积相对于完全切除的生存劣势。

研究设计与样本

  • 回顾性分析2010至2018年单中心神经肿瘤科收治的IDH野生型胶质母细胞瘤(WHO IV级)术后有残留肿瘤的患者,共纳入81例,并与完全切除患者比较。

主要发现

  • 81例残留肿瘤患者中31例(38.27%)MGMT启动子甲基化。
  • MGMT甲基化患者中位OS为16个月 vs 13个月(p=0.009),中位PFS为13个月 vs 5个月(p=0.003)。
  • 与完全切除患者相比,残留肿瘤患者无论MGMT甲基化状态如何,OS均降低。

临床怎么用

  • 对于IDH野生型胶质母细胞瘤,应充分权衡残留肿瘤体积与完全切除可能带来的神经功能缺损,个体化讨论手术切除程度。

局限性

  • 回顾性单中心研究,样本量有限(残留肿瘤患者81例),结论需更大队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact on survival of complete resection (CR) in patients with malignant glioma and MGMT promoter methylation on adjuvant therapy strategies has been proven in the past. However, it is not known whether a MGMT promoter methylation can compensate a subtotal resection. Therefore, we analyzed the progress of postoperative residual tumor tissue depending on the molecular tumor status. METHODS: We included all glioblastoma, IDH-wildtype (WHO grade IV) patients with postoperative residual tumor tissue, who were treated at our neurooncological department between 2010 and 2018. Correlation of molecular patterns with clinical data and survival times was performed. The results were compared to patients following CR. RESULTS: 267 patients with glioblastoma, IDH-wildtype (WHO grade IV) received surgery of whom 81 patients with residual tumor were included in the analysis. MGMT promoter was methylated in 31 patients (38.27%). Median OS and PFS were significantly increased in patients with methylated MGMT promoter (mOS: 16 M vs. 13 M, p = 0.009; mPFS: 13 M vs. 5 M, p = 0.003). In comparison to survival of patients following CR, OS was decreased in patients with residual tumor regardless MGMT methylation. CONCLUSION: Our data confirm impact of MGMT promoter methylation in patients with glioblastoma, IDH-wildtype on OS and PFS. However, in comparison to patients after CR, a methylated MGMT promoter cannot compensate the disadvantage due to residual tumor volume. In terms of personalized medicine and quality of life as major goal in oncology, neuro-oncologists have to thoroughly discuss advantages and disadvantages of residual tumor volume versus possible neurological deficits in CR.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Mareike M, Franziska SB, Julia E, et al. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients? J Neurooncol. 2021. PMID: 34185258. doi:10.1007/s11060-021-03794-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。